# JS212 Combination Therapies in Metastatic Colorectal Cancer

> **NCT07503756** · PHASE2 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** JS212
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** JS207

## Key facts

- **NCT ID:** NCT07503756
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-25
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07503756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07503756, "JS212 Combination Therapies in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07503756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*